Free Trial

Carisma Therapeutics (CARM) Competitors

-0.04 (-3.51%)
(As of 07/19/2024 ET)


Should you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Cytosorbents (CTSO), Exagen (XGN), LifeVantage (LFVN), Aspira Women's Health (AWH), Adverum Biotechnologies (ADVM), Abeona Therapeutics (ABEO), Renovaro (RENB), Generation Bio (GBIO), Seres Therapeutics (MCRB), and Eliem Therapeutics (ELYM). These companies are all part of the "medical" sector.

Carisma Therapeutics vs.

Cytosorbents (NASDAQ:CTSO) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.

Cytosorbents has a net margin of -75.07% compared to Cytosorbents' net margin of -538.81%. Carisma Therapeutics' return on equity of -129.89% beat Cytosorbents' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytosorbents-75.07% -129.89% -54.98%
Carisma Therapeutics -538.81%-215.95%-80.58%

Cytosorbents has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.

Cytosorbents has higher revenue and earnings than Carisma Therapeutics. Cytosorbents is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$14.92M3.06-$86.88M-$2.00-0.55

Cytosorbents received 423 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 78.28% of users gave Cytosorbents an outperform vote.

CytosorbentsOutperform Votes
Underperform Votes
Carisma TherapeuticsOutperform Votes
Underperform Votes
No Votes

Cytosorbents presently has a consensus price target of $2.00, suggesting a potential upside of 90.48%. Carisma Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 627.27%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Cytosorbents.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
Carisma Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)

In the previous week, Cytosorbents had 3 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Cytosorbents and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.37 beat Cytosorbents' score of 0.00 indicating that Cytosorbents is being referred to more favorably in the media.

Company Overall Sentiment
Cytosorbents Neutral
Carisma Therapeutics Neutral

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by insiders. Comparatively, 17.0% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Cytosorbents and Carisma Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CARM vs. The Competition

MetricCarisma TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$45.69M$7.06B$5.29B$8.23B
Dividend YieldN/A2.70%2.81%3.95%
P/E Ratio-0.5512.27131.9815.76
Price / Sales3.06280.422,167.7278.43
Price / CashN/A32.1935.8833.93
Price / Book1.675.734.864.42
Net Income-$86.88M$147.21M$111.70M$216.15M
7 Day Performance-8.33%-2.42%-0.66%-0.11%
1 Month Performance8.91%6.57%7.53%5.61%
1 Year Performance-87.57%-4.24%4.27%1.32%

Carisma Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
0.8946 of 5 stars
0.89 / 5 stars
-71.1%$56.48M$36.35M-1.76220Analyst Forecast
News Coverage
Gap Up
4.6325 of 5 stars
4.63 / 5 stars
-21.9%$35.78M$52.55M-1.89174Gap Up
3.0431 of 5 stars
3.04 / 5 stars
N/A+36.6%$80.14M$213.40M22.54248Short Interest ↓
News Coverage
Positive News
Aspira Women's Health
1.7525 of 5 stars
1.75 / 5 stars
-46.2%$18.68M$9.15M-1.0364News Coverage
Adverum Biotechnologies
4.8811 of 5 stars
4.88 / 5 stars
-61.6%$156.53M$3.60M-0.74121Analyst Forecast
Insider Buying
Short Interest ↓
News Coverage
Gap Up
High Trading Volume
Abeona Therapeutics
4.2635 of 5 stars
4.26 / 5 stars
+36.6%$215.45M$3.50M-1.64N/APositive News
0.7716 of 5 stars
0.77 / 5 stars
N/AN/A$213.89MN/A-1.8612News Coverage
Generation Bio
3.3465 of 5 stars
3.35 / 5 stars
-45.2%$211.57M$5.90M-1.25174Short Interest ↑
Positive News
Seres Therapeutics
3.6371 of 5 stars
3.64 / 5 stars
-73.1%$209.86M$126.32M-2.31330News Coverage
Eliem Therapeutics
0.5173 of 5 stars
0.52 / 5 stars
N/A+145.0%$206.78MN/A-13.119Insider Selling
News Coverage

Related Companies and Tools

This page (NASDAQ:CARM) was last updated on 7/21/2024 by Staff

From Our Partners